The prognostic value of HER-2/neu status in premenopausal patients with hormone-responisve breast cancer
Jakesz R, Hausmaninger H, Kubista E, Gnant M, Seifert M, Kwasny W, Steger G, Samonigg H, Tausch C, Stierer M
San Antonio Breast Cancer Symposium
Standards in der Mamma-Ca-Therapie
Wiener Klinische Wochenschrift
Overexpression of hypoxia-inducible factor 1alpha is associated with an unfavorable prognosis in lymph node-positive breast cancer
Schindl M, Schoppmann F, Samonigg H, Hausmaninger H, Kwasny W, Gnant M, Jakesz R, Kubista E, Birner P, Oberhuber G
Clinical Cancer Research 2002 Jun;8(6):1831-7.
Influence of anemia on local relapse free survival (LRFS) of premenopausal primary breast cancer patients under adjuvant CMF chemotherapy: An analysis of the Austrian Breast Cancer Study Group
Sevelda P, Gnant M
American Society of Clinical Oncology
The prognostic influence of body mass index in premenopausal breast cancer patients
Taucher S, Gnant M, Hausmaninger H, Kubista E, Samonigg H, Steger G, Stierer M, Tausch C, Jakesz R
San Antonio Breast Cancer Symposium
Pilot-trial of trastuzumab + weekly epidoxorubicin/docetaxel in the neoadjuvant treatment of primary breast cancer – Preliminary results
Steger G, Wenzel C, Locker G, Rudas M, Gnant M, Taucher S, Zielinski C, Jakesz R
American Society of Clinical Oncology, 2002
Survival of women with breast cancer in Austria by age, stage and period of diagnosis
Vutuc Chr, Waldhoer T, Klimot J, Haidinger G, Jakesz R, Kubist E, Zielinski C
Wiener Klinische Wochenschrift 2002;114(12):438-442
Division of Epidemiology, Institute for Cancer Research, Medical School, University of Vienna, Austria. firstname.lastname@example.org
To investigate survival of breast cancer patients by 1) age, 2) tumor stage and 3) period of diagnosis, also to determine the contribution of improvements in treatment and opportunistic mammography screening in Austria.
Survival was calculated overall and by 1) age groups (in years) < 50, 50-64, > 65; 2) stage I, II, IV, unknown 3) for 17,025 patients diagnosed 1988-92, compared with 19,284 patients diagnosed 1993-97. Odds ratios for being diagnosed as stage I in the period 1993-97 compared to 1988-92 were calculated by age group and for all ages.
In the later period (1993-97) age-adjusted mortality rate decreased overall by 3.3% (age: < 50; 8.2%, 50-64; 5.1%, > 65; 1.6%). Overall, stage I cases increased from 46.5% to 51%. Five year relative survival rates improved significantly overall, 6.7% (p < 0.001), and within age groups (age: < 50; 4.5% (p < 0.05), 50-64; 7.2% (p < 0.05) and > 65; 7.3% (p < 0.001). This improvement is confined to patients with stage I tumors in age groups 50-64 (4.1%, p < 0.05) and > 65 (7.2%, p < 0.001) and to patients with stage II in age groups < 50 (7.7%, p < 0.01) and 50-64 (8.3%, p < 0.01). For patients younger than 50, in stage IV, diagnosed 1993-97, survival was significantly poorer (-16.9%, p < 0.05) compared to 1988-92. The odds ratio of being diagnosed as stage I in the later period was 1.19 (95% CI: 1.14, 1.24) for all ages, 1.13 (95% CI: 1.03, 1.24) and for women < 50, 1.3 (95% CI: 1.20, 1.40) 50-64 and 1.15 (95% CI: 1.09, 1.22) > 65 years old.
We conclude that treatment improvements, which are accessible to all patients countrywide due to the compulsory state insurance system, had a major impact on positive trends in mortality and survival. Opportunistic screening should have contributed to some extent beginning in the early nineties.
Chemotherapy versus hormonal adjuvant treatment in premenopausal patients with breast cancer
R Jakesz, H Hausmaninger, H Samonigg
European Journal of Cancer 38 (2002) 327–332
Randomized Adjuvant Trial of Tamoxifen and Goserelin Versus Cyclophosphamide, Methotrexate, and Fluorouracil: Evidence for the Superiority of Treatment With Endocrine Blockade in Premenopausal Patients With Hormone-Responsive Breast Cancer – Austrian Breast and Colorectal Cancer Study Group – Trial 5
Raimund Jakesz, Hubert Hausmaninger, Ernst Kubista, Michael Gnant, Christian Menzel, Thomas Bauernhofer, Michael Seifert, Karin Haider, Brigitte Mlineritsch, Peter Steindorfer, Werner Kwasny, Michael Fridrik, Guenther Steger, Viktor Wette, and Hellmut Samonigg
J Clin Oncol 20:4621-4627, 2002